Global health research investments generate economic returns and medical breakthroughs that benefit high-income countries. Between 2008 and 2024, U.S. government institutions such as the National Institutes of Health spent approximately $46 billion on global health initiatives targeting neglected diseases, emerging infectious diseases, and sexual and reproductive health. That federal expenditure catalyzed $104 billion in total economic activity and created 600,000 jobs within the United States.
Financial Returns Drive U.S. Economic Activity
National Institutes of Health estimated that every $1 invested in global health research yields a return on investment of $2.21 while creating seven American jobs.
Innovation Spillovers Transform Domestic Medicine
Investments directed toward international health threats frequently yield unexpected medical interventions for patients in high-income nations. A recent clinical case in the United States involved a patient treated for eyelid inflammation and dry eyes using ivermectin, a medication originally developed to combat onchocerciasis, or river blindness, a parasitic disease transmitted by blackflies in rural sub-Saharan Africa. The nonprofit research organization Impact Global Health tracks these transfers as innovation spillovers, connecting international disease eradication efforts to domestic treatments for conditions ranging from breast cancer risk reduction to pediatric cancers.
Historical partnerships illustrate how international research yields foundational technologies for domestic immunization schedules. A 1980s research collaboration between GlaxoSmithKline and the Walter Reed Army Institute of Research developed a lifesaving malaria vaccine that prevents up to one in eight childhood deaths in malaria-affected regions of sub-Saharan Africa. The underlying technology driving that malaria vaccine serves as the structural basis for shingles and RSV vaccines currently deployed globally. Industry projections estimate the shingles vaccine will prevent over 9 million cases in the U.S. and save the health care system $55 billion by 2050.
Century-Old Tuberculosis Vaccine Yields Modern Cancer Therapies
Interventions developed for infectious diseases overseas continue to influence domestic oncology standards decades later. French scientists developed a tuberculosis vaccine over a century ago to address a lung infection that currently kills over 1 million people annually, with 80% of fatalities occurring in low- and middle-income countries. In 1990, the U.S. Food and Drug Administration approved the active medication within that tuberculosis vaccine as an intravesical treatment for bladder cancer. Researchers project this adaptation will prevent more than 300,000 cancer recurrences, save nearly 100,000 lives, and reduce U.S. health care expenditures by nearly $12 billion by 2050.
What federal institutions fund global health research?
What specific federal institutions fund global health research in the United States?
U.S. government institutions such as the National Institutes of Health allocated approximately $46 billion between 2008 and 2024 across neglected diseases, emerging infectious diseases, and sexual and reproductive health programs.
How much economic return does the National Institutes of Health estimate per dollar invested?
National Institutes of Health estimated that every $1 invested in global health research generates a return on investment of $2.21 and creates seven American jobs.
What disease was ivermectin originally created to treat?
Ivermectin is primarily used to treat onchocerciasis, commonly known as river blindness, a condition caused by a parasitic worm transmitted by infected blackflies in rural sub-Saharan Africa.
When was the tuberculosis vaccine medication approved for cancer treatment in the U.S.?
The U.S. Food and Drug Administration approved the medication utilized in the tuberculosis vaccine as a treatment for bladder cancer in 1990.
Related reading